9522 Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize this invention. Interested 

parties should have the ability to 

manufacture viruses under cGMP, 

suitable for Phase 1–2 testing by NIAID. 

Capabilities for further clinical 

development, and experience with 

Phase 3 testing, licensure, and rollout 

are preferred. For collaboration 

opportunities, please contact Chris 

Kornak at chris.kornak@nih.gov. 

Dated: January 29, 2021. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–03044 Filed 2–12–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Director, National 

Institutes of Health; Notice of Meeting 

Notice is hereby given of a meeting of 

the HEAL (Helping to End Addiction 

Long-term) Multi-Disciplinary Working 

Group 

The meeting will be open to the 

public as indicated below via NIH 

Videocast. Individuals who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The program documents 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the program 

documents, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: HEAL MultiDisciplinary Working Group Meeting. 

Date: March 2–3, 2021. 

Open: March 02, 2021, 11:00 a.m. to 12:20 

p.m. 

Closed: March 02, 2021, 12:20 p.m. to 4:30 

p.m. 

Open: March 03, 2021, 10:30 a.m. to 11:05 

a.m. 

Closed: March 03, 2021, 11:05 a.m. to 2:45 

p.m. 

Agenda: Provide an update on Helping to 

End Addiction Long-Term (HEAL) Initiative 

projects and obtain expertise from MDWG 

relevant to the NIH HEAL Initiative and to 

specific HEAL projects. 

Videocast: The open portion of the meeting 

will be live webcast at: https://

videocast.nih.gov/. 

Place: National Institutes of Health 

Building 1, Wilson Hall, 1 Center Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rebecca G Baker, Ph.D., 

Office of the Director, National Institutes of 

Health, 1 Center Drive, Room 103A, 

Bethesda, MD 20892, (301) 402–1994, 

Rebecca.baker@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the Office 

of the Director for the NIH HEAL Initiative 

home page: https://heal.nih.gov/news where 

an agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: February 9, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–03018 Filed 2–12–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice of Diabetes Mellitus Interagency 

Coordinating Committee Meeting 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Diabetes Mellitus 

Interagency Coordinating Committee 

(DMICC) will hold a meeting on March 

3, 2021. The topic for this meeting will 

be ‘‘COVID–19 and Diabetes.’’ The 

meeting is open to the public. 

DATES: The meeting will be held on 

March 3, 2021 from 12 noon to 4:00 

p.m. EST. 

ADDRESSES: The meeting will be held 

via the online video conferencing— 

Zoom. For details, and to register, please 

contact dmicc@mail.nih.gov. 

FOR FURTHER INFORMATION CONTACT: For 

further information concerning this 

meeting, including a draft agenda, see 

the DMICC website, 

www.diabetescommittee.gov, or contact 

Dr. B. Tibor Roberts, Executive 

Secretary of the Diabetes Mellitus 

Interagency Coordinating Committee, 

National Institute of Diabetes and 

Digestive and Kidney Diseases, 31 

Center Drive, Building 31A, Room 

9A19, MSC 2560, Bethesda, MD 20892– 

2560, telephone: 301–496–6623; FAX: 

301–480–6741; email: dmicc@

mail.nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 42 U.S. Code 285c–3, 

the DMICC, chaired by the National 

Institute of Diabetes and Digestive and 

Kidney Diseases (NIDDK) comprising 

members of the Department of Health 

and Human Services and other federal 

agencies that support diabetes-related 

activities, facilitates cooperation, 

communication, and collaboration on 

diabetes among government entities. 

DMICC meetings, held several times a 

year, provide an opportunity for 

Committee members to learn about and 

discuss current and future diabetes 

programs in DMICC member 

organizations and to identify 

opportunities for collaboration. The 

March 3, 2021 DMICC meeting will 

focus on ‘‘COVID–19 and Diabetes.’’ 

Any member of the public interested 

in presenting oral comments to the 

Committee should notify the contact 

person listed on this notice at least 5 

days in advance of the meeting. 

Interested individuals and 

representatives or organizations should 

submit a letter of intent, a brief 

description of the organization 

represented, and a written copy of their 

oral presentation in advance of the 

meeting. Only one representative of an 

organization will be allowed to present; 

oral comments and presentations will be 

limited to a maximum of 5 minutes. 

Printed and electronic copies are 

requested for the record. In addition, 

any interested person may file written 

comments with the Committee by 

forwarding their statement to the 

contact person listed on this notice. The 

statement should include the name, 

address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Because of time constraints for the 

meeting, oral comments will be allowed 

on a first-come, first-serve basis. 

Members of the public who would 

like to receive email notification about 

future DMICC meetings should register 

for the listserv available on the DMICC 

website, www.diabetescommittee.gov. 


khammond on DSKJM1Z7X2PROD with NOTICES